Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491–8.
Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375:944–53.
Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, et al. Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 2020;95:343–53.
Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117:2332–9.
Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, et al. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016;172:360–70.
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transpl. 2017;23:882–96.
Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134:924–34.
Ruggeri A. Optimizing cord blood selection. Hematol Am Soc Hematol Educ Program. 2019;1:522–31.
Politikos I, Davis E, Nhaissi M, Wagner JE, Brunstein CG, Cohen S, et al. Guidelines for cord blood unit selection. Biol Blood Marrow Transpl. 2020;26:2190–6.
Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transpl. 2011;46:70–6.
Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol. 2009;147:262–74.
Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, et al. Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. Blood. 2013;121:752–8.
Wagner JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371:1685–94.
Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100:1611–8.
Konuma T, Kato S, Oiwa-Monna M, Tanoue S, Ogawa M, Isobe M, et al. Cryopreserved CD34+ cell dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transpl. 2017;23:1142–50.
Migliaccio AR, Adamson JW, Stevens CE, Dobrila NL, Carrier CM, Rubinstein P. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood. 2000;96:2717–22.
Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T, et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transpl. 2011;17:1362–74.
Broxmeyer HE. Predicting the quality of transplantable cord blood collections through prefreeze and postthaw Apgar scoring. Transfusion. 2012;52:219–21.
Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Shoulars K, et al. The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation. Transfusion. 2012;52:272–83.
Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Impact of donor-recipient HLA-matching at HLA-A, -B, -C, and –DRB1 on outcomes after umbilical cord blood transplantation for leukemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12:1214–21.
Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133–40.
Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, et al. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017;4:e325–33.
Gluckman E. Role of HLA matching in single umbilical cord blood transplantation outcomes. Biol Blood Marrow Transpl. 2020;26:e53–4.
Kanda J, Kawase T, Tanaka H, Kojima H, Morishima Y, Uchida N, et al. Effects of haplotype matching on outcomes after adult single-cord blood transplantation. Biol Blood Marrow Transpl. 2020;26:509–18.
Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, et al. Impact of HLA mismatch at HLA-A, -B, -C, and –DRB1 in single cord blood transplantation. Biol Blood Marrow Transpl. 2020;26:519–28.
Ishwaran H, Gerds TA, Kogalur UB, Moore RD, Gange SJ, Lau BM. Random survival forests for competing risks. Biostatistics. 2014;15:757–73.
Breiman L. Random forests. Mach Learn. 2001;45:5–32.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
Sobol U, Go A, Kliethermes S, Bufalino S, Rodriguez T, Smith S, et al. A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transpl. 2015;50:1519–25.
Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–54.
Hussein E, DeFor T, Wagner JE, Sumstad D, Brunstein CG, McKenna DH. Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant. Transfusion. 2020;60:144–54.
Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood. 2010;115:1843–9.
Castillo N, Garcia-Cadenas I, Barba P, Martino R, Azqueta C, Ferra C, et al. Post-thaw viable CD45+ cells and clonogenic efficiency are associated with better engraftment and outcomes after single cord blood transplantation in adult patients with malignant diseases. Biol Blood Marrow Transpl. 2015;21:2167–72.
Scaradavou A, Smith KM, Hawke R, Schaible A, Abboud M, Kernan NA, et al. Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation. Biol Blood Marrow Transpl. 2010;16:500–8.
Ponce DM, Lubin M, Gonzales AM, Byam C, Wells D, Ferrante R, et al. The use of back-up units to enhance the safety of unrelated donor cord blood transplantation. Biol Blood Marrow Transpl. 2012;18:648–51.
Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 2013;98:814–22.
Yanada M, Konuma T, Kuwatsuka Y, Kondo T, Kawata T, Takahashi S, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. Bone Marrow Transpl. 2019;54:1789–98.
Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, et al. Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. Leukemia. 2020;34:128–37.